Education
About Us
Working with TipRanks
Follow Us
Symbio Pharmaceuticals Limited (JP:4582)
:4582
Total Valuation
Symbio Pharmaceuticals Limited has a market cap or net worth of ¥7.20B. The enterprise value is ¥6.90B.
Market Cap¥7.20B
Enterprise Value¥6.90B
Share Statistics
Symbio Pharmaceuticals Limited has 59,567,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,567,080
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Symbio Pharmaceuticals Limited’s return on equity (ROE) is -3.75 and return on invested capital (ROIC) is -136.24%.
Return on Equity (ROE)-3.75
Return on Assets (ROA)-1.24
Return on Invested Capital (ROIC)-136.24%
Return on Capital Employed (ROCE)-1.72
Revenue Per Employee12.11M
Profits Per Employee-44.22M
Employee Count108
Asset Turnover0.34
Inventory Turnover1.25
Valuation Ratios
The current PE Ratio of Symbio Pharmaceuticals Limited is ―. Symbio Pharmaceuticals Limited’s PEG ratio is -0.08.
PE Ratio―
PS Ratio3.46
PB Ratio3.55
Price to Fair Value3.55
Price to FCF-0.99
Price to Operating Cash Flow0.00
PEG Ratio-0.08
Income Statement
In the last 12 months, Symbio Pharmaceuticals Limited had revenue of 1.31B and earned -4.78B in profits. Earnings per share was -95.12.
Revenue1.31B
Gross Profit947.34M
Operating Income-4.44B
Pretax Income-4.75B
Net Income-4.78B
EBITDA-4.60B
Earnings Per Share (EPS)-95.12
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Symbio Pharmaceuticals Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-10.61%
50-Day Moving Average93.54
200-Day Moving Average132.71
Relative Strength Index (RSI)82.03
Average Volume (3m)577.10K
Important Dates
Symbio Pharmaceuticals Limited upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateFeb 5, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Symbio Pharmaceuticals Limited as a current ratio of 2.96, with Debt / Equity ratio of 155.85%
Current Ratio2.96
Quick Ratio2.74
Debt to Market Cap0.44
Net Debt to EBITDA0.20
Interest Coverage Ratio-29.71
Taxes
In the past 12 months, Symbio Pharmaceuticals Limited has paid 27.57M in taxes.
Income Tax27.57M
Effective Tax Rate>-0.01
Enterprise Valuation
Symbio Pharmaceuticals Limited EV to EBITDA ratio is -0.79, with an EV/FCF ratio of -0.79.
EV to Sales2.77
EV to EBITDA-0.79
EV to Free Cash Flow-0.79
EV to Operating Cash Flow-0.79
Balance Sheet
Symbio Pharmaceuticals Limited has ¥3.05B in cash and marketable securities with ¥1.30B in debt, giving a net cash position of ¥1.75B billion.
Cash & Marketable Securities¥3.05B
Total Debt¥1.30B
Net Cash¥1.75B
Net Cash Per Share¥29.44
Tangible Book Value Per Share¥25.33
Margins
Gross margin is 72.45%, with operating margin of -339.59%, and net profit margin of -365.25%.
Gross Margin72.45%
Operating Margin-339.59%
Pretax Margin-363.14%
Net Profit Margin-365.25%
EBITDA Margin-351.71%
EBIT Margin-351.71%
Analyst Forecast
The average price target for Symbio Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-50.27%
EPS Growth Forecast-3.33%